Predictability of C-peptide for autoimmune diabetes in young adult diabetic patients

Practical Diabetes International

Volumn 18, Issue 3, 2001, Pages 83-88

  Kamal, A D ^a   Kesson, C M ^a   Rooney, D P ^a  

^a VICTORIA INFIRMARY   (United Kingdom)

Author keywords

C peptide; Data collection; Diabetes mellitus; Differential diagnosis; Immunologic monitoring

Indexed keywords

ANTIBODY; C PEPTIDE; CARBOXYLASE; GLUTAMIC ACID; INSULIN; PANCREAS ISLET CELL ANTIBODY; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FOOD INTAKE; HUMAN; IMMUNOLOGICAL MONITORING; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PREDICTION; PROTEIN BLOOD LEVEL; STANDARDIZATION;

EID: 0035008361     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.125     Document Type: Article

References (20)

1. 1 Polonsky KS, Rubenstein AH. C‐peptide as a measure of the secretion and hepatic extraction of insulin, pitfalls and limitations. Diabetes 1984 ; 33: 486–494.
2. 2 Landin‐Olsson M, Karlsson FA, Lernmark Å, et al. Islet cell and thyrogastric antibodies in 633 consecutive 15–34 years old patients in the Diabetes Incidence Study in Sweden (DISS). Diabetes 1992 ; 41: 1022–1027.
3. 3 Gepts W, LaCompte PM. The pancreatic islets in diabetes. Am J Med 1981 ; 70: 105–115.
4. 4 Hummel M, Durinovic‐Bello I, Ziegler A‐G. Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. J Autoimmun 1996 ; 9: 427–430.
5. 5 Duranovic‐Bellò I, Hummel M, Ziegler AG. Cellular immune response to diverse islet cell antigens in IDDM. Diabetes 1996 ; 45: 795–800.
6. 6 Polonsky KS. Lilly Lecture 1994. The beta cell in diabetes: From molecular genetics to clinical research. Diabetes 1995 ; 44: 705–717.
7. 7 World Health Organization Technical Report Series No 727: Diabetes Mellitus, report of a WHO Study Group. Geneva: WHO, 1985.
8. 8 Landin‐Olsson M, Sundkvist G, Lernmark Å. Prolonged incubation in the two‐colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin‐dependent) diabetes mellitus. Diabetologia 1987 ; 30: 327–332.
9. 9 Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA‐2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes. Diabetes 1998 ; 47: 1857–1866.
10. 10 Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform‐specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994 ; 37: 344–350.
11. 11 Falorni A, Örtqvist E, Persson B, et al. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35 S or 3 H recombinant human ligands. J Immunol Methods 1995 ; 186: 89–99.
12. 12 Gianani R, Rabin DU, Verge CF, et al. ICA512 autoantibody radioassay. Diabetes 1995 ; 44: 1340–1344.
13. 13 Zweig M, Campbell G. Receiver‐operating characteristics (ROC) plots: a fundamental tool in clinical medicine. Clin Chem 1993 ; 39: 561–577.
14. 14 Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998 ; 102: 619–624.
15. 15 Rosetti L, Giaccari A, Defronzo RA. Glucose toxicity. Diabetes Care 1990 ; 13: 610–630.
16. 16 Junti‐Berggren L, Pigon J, Karpe F, et al. The antidiabetogenic effect of GLP‐1 is maintained during a 7‐day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996 ; 19: 1200–1206.
17. 17 Gutniak M, Larsson H, Sanders SW, et al. GLP‐1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 1997 ; 20: 1874–1879.
18. 18 Simonsson E, Karlsson S, Ahrén B. Ca 2+ ‐independent phospholipase A 2 contributes to the insulinotropic action of cholecystokinin‐8 in rat islets. Diabetes 1998 ; 47: 1436–1443.
19. 19 Savola K, Bonifacio E, Sabbah E, et al. IA‐2 antibodies ‐ a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 1998 ; 41: 424–429.
20. 20 Vandewalle CL, Falorni A, Svanholm S, et al. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in IDDM with clinical onset between age 20 and 40 years. J Clin Endocrinol Metab 1995 ; 80: 846–850.